Subtotal: $1,761.00
Original price was: $3,699.00.$3,499.00Current price is: $3,499.00.
In Stock
Perjeta.
Metastatic breast cancer
In combination with trastuzumab and docetaxel for metastatic or locally recurrent, inoperable breast cancer with tumor overexpression of HER2 in the absence of previous HER2-specific therapy or chemotherapy for metastatic disease.
Non-metastatic breast cancer
In combination with trastuzumab and chemotherapy:
as a neoadjuvant therapy for locally advanced, edematous infiltrative or early (primary operable) breast cancer (tumor diameter more than 2 cm or with lymph node involvement) with HER2 overexpression as part of a complete treatment regimen for early breast cancer;
as an adjuvant therapy for early (primary operable) breast cancer with HER2 overexpression.
Active ingredient: pertuzumab
Storage temperature 4-8 degrees
Prescription medicine
